Immune Checkpoint Proteins

Similar documents
A fresh approach to Immuno-oncology: Ex vivo analysis of drug efficacy in fresh patient tumortissue

T Cell Activation, Costimulation and Regulation

Welcome. Nanostring Immuno-Oncology Summit. September 21st, FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.

Tumor Immunity and Immunotherapy. Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School

Understanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies. Michael A. Curran, Ph.D.

MHC Tetramers and Monomers for Immuno-Oncology and Autoimmunity Drug Discovery

C M. Chimerigen Laboratories C M. Biologically Active BULK Proteins. Butyrophilin-like 2 [BTNL2] mil-35/fc An Inhibitory Cytokine.

Novel Reporter Gene Bioassays for Immunotherapy Drug Research and Development Jey Cheng, PhD Sr Research Scientist Promega Corporation

Immunology. Antibodies for immunology research

Cancer immunity and immunotherapy. General principles

Reporter Gene Immunotherapy Bioassays

Coxsackievirus A21: The basic facts

ACE ImmunoID Biomarker Discovery Solutions ACE ImmunoID Platform for Tumor Immunogenomics

Discover the PD-1 pathway and its role in cancer 105/15 -ONCO- 07/15

Immune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich

DISCOVER MORE WITH LESS SAMPLE. nanostring.com/3d

ASCO 2018 Investor Meeting

International Society of Breast Pathology. Immune Targeting in Breast Cancer. USCAP 2017 Annual Meeting

AlphaScreen : A Straightforward and Powerful Alternative to ELISA. Martina Bielefeld-Sévigny Ph.D., R&D Director

Data Sheet PD-1 / NFAT Reporter - Jurkat Cell Line Catalog #: 60535

Immuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017

Venky Ramakrishna PhD Celldex Therapeutics, Hampton NJ, USA

IMMUNOTHERAPY OVERVIEW. Gloria Roldan Urgoiti MD, MSc, FRCPC Tom Baker Cancer Centre April 22, 2017

A Multifaceted Immunomonitoring to Identify Predictive Biomarkers for the Clinical Outcome of Immunotherapy-Treated Melanoma Patients

Data Sheet TIGIT / NFAT Reporter - Jurkat Cell Line Catalog #60538

Tumor Microenvironment and Immune Suppression

Blocking antibodies and peptides. Rat anti-mouse PD-1 (29F.1A12, rat IgG2a, k), PD-

Nuovi approcci immunoterapici nel trattamento del Melanoma: Background immunologico.

Heat Biologics. Corporate Presentation March 9, 2018

Paediatric strategy forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients

Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment

Tim-3 as a target for tumor immunotherapy

Immuno-Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. February 24, 2016

Data Sheet PD-1 / NFAT Reporter - Jurkat Cell Line Catalog #: 60535

BIOASSAYS IN PRODUCT DEVELOPMENT: An Immuno-Oncology Perspective

The broadest portfolio for your T cell research

AlphaScreen TNFα Binding Assay Kit: A Homogeneous, Sensitive and High-Throughput Assay for Screening TNFα Receptors

Identification of novel immune regulators of tumor growth using highthroughput

Next generation of immune checkpoint therapy in cancer: new developments and challenges

Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic

Immune Tolerance. Kyeong Cheon Jung. Department of Pathology Seoul National University College of Medicine

Knowledge wins. Immuno-oncology

Basic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression. Bryon Johnson, PhD

Immune Checkpoint Inhibitors Drug Combinations: Patients Relevance & Ways Forward

Molecular mechanisms of T cell co stimulation and co inhibition

Biologic Basis of Immunotherapy in Lung Cancer

NOYCIA Validation of the Princess Margaret Immune Oncology Prognostic Index (PM-IPI) for patients treated in immune oncology early phase trials

Role of the pathologist in the diagnosis and mutational analysis of lung cancer Professor J R Gosney

Giorgio V. Scagliotti Università di Torino Dipartimento di Oncologia

Combination Therapies Based on PD-1 or PD-L1 Blockade

Superior Fluorescent Labeling Dyes Spanning the Full Visible Spectrum...1. Trademarks: HiLyte Fluor (AnaSpec, Inc.)

Novel Approaches to CAR-T Cell Platform

Detection of immune cell checkpoint and functional markers in the tumor microenvironment by the RNA in situ hybridization RNAscope assay

Immunocore and MedImmune announce new collaboration to conduct immuno-oncology combination trials in melanoma

Accepted Manuscript. Next Steps for Immune Checkpoints in Hepatocellular Carcinoma. Patricia M. Santos, Lisa H. Butterfield

IMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust

Utilizing AlphaLISA Technology to Screen for Inhibitors of the CTLA-4 Immune Checkpoint

Immuno-Oncology: Essentials for Nurses in Cancer Care

Data Sheet. CD28:B7-2[Biotinylated] Inhibitor Screening Assay Kit Catalog # Size: 96 reactions

Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017

Supplemental Materials

Darwinian selection and Newtonian physics wrapped up in systems biology

Rational combinations with immunotherapeutics

ONCOSEC ARMING THE IMMUNE SYSTEM TO FIGHT CANCER NASDAQ: ONCS

The Galectin-3 Inhibitor GR-MD-02 for Combination Cancer Immunotherapy

Corporate Presentation November Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers

TGFβR1 Kinase Inhibitor

vol.3 Highlight Product: ExoCap Product Research tools for extracellular vesicles - Exhibition booth at Taiwan on November

Dra. Omayra Reyes, MD. Hematologist- Oncologist. Introduction to Immuno Oncology

PD-L1, PD-1, LAG-3, CD40, CD86, CD27, CD70

Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game?

ONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan

Cancer and the Immune System

Cytokine Arrays Reveal Black Ops Tactics of Tumor-induced Immunosuppression

TGFβR1 Kinase Inhibitor

New Developments in the Treatment of Colorectal Cancer. Jonathan Loree, MD, MS, FRCPC Department of Medical Oncology BC Cancer Vancouver Centre

ALLIGATOR BIOSCIENCE AB (PUBL) 30 January 2018 Per Norlén, CEO

Providence Cancer Center, Portland, OR; 2 Oncology Specialists, Chicago, IL; 3 John Wayne Cancer InsPtute, Santa Monica, CA; 4

Immunotherapy of Hepatocellular Carcinoma Where are we now?

Overview for today. NSG and NSG -SGM3 are a proven platform. A growing list of drugs have shown translationally relevant response

GSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017

TNF Superfamily Receptor Modulators Innovative Immuno-Oncology Therapeutics BioRN Lounge,

Therapeutic Targets of the TNF Superfamily

Basic mechanisms of Immunotherapy

Corporate Presentation March 2016

Advances in Systemic Therapy Hepatocellular Carcinoma (HCC) Dr ZEE Ying Kiat HASLD Conference Ho Chi Minh City, 18 December 2016

IMMUNOTHERAPY IMMUNOTHERAPY. CHI Immuno-oncology Summit Boston. 27 th August 2018

Extracellular Vesicle Quantification Kits

The Need for a PARP in vivo Pharmacodynamic Assay

Innate Immunity & Inflammation

Immunotherapy in Colorectal cancer

Immunotherapy of HNC: immune mechanisms and therapeutic targets

Dilution Factor Serum Plasma Urine CSF (Other)

DBC 25-Hydroxyvitamin D

More cancer patients are being treated with immunotherapy, but

Immune Checkpoint Blockade against Malignancy. Blocking Self-inflicted Inhibitions?

Strep-tag HRP Detection Kit (Horse Radish Peroxidase)

The Emergence of Universal Immune Receptors for Highly Personalized T cell Therapy

Utilizing Humanized NSG Mice to Evaluate Drug Efficacy in Immuno-Oncology

Concurrent Chemo- and Radiotherapy for Ororpharynx Cancer

Transcription:

Immune Checkpoint Proteins www.acrobiosystems.com

Content I. Introduction II. Biotinylated Immune Checkpoint Proteins III. PD1:PDL1 Inhibitor Screening Assay Kit IV. HPLC-Verified Checkpoint Proteins V. Product List OX40 ICOS B7-H2 LAG-3 TIM-3

Introduction In recent years, immune checkpoint proteins have attracted increasing attention due to their involvement in cancer development. Often times, tumor cells can hijack the checkpoint pathways to avoid attacks from the immune system. Therefore, many believe that disabling immune checkpoints would help re-engage the body s immune system to fight against cancers. Intriguingly, anti-ctla4 and anti-pd1 monoclonal antibodies have already demonstrated anti-tumor effect in patients with a variety of malignancies. Encouraged by this early success, researchers have expanded their investigations into other checkpoint proteins in order to find better ways to treat cancer. To support these efforts, ACROBiosystems has developed an exclusive immune checkpoint protein collection. These products have demonstrated consistent and excellent performance in a variety of assays. Featured Product: Biotinylated Immune Checkpoint Proteins In addition to standard recombinant protein product, we offer a collection of pre-labeled and pre-validated biotinylated checkpoint proteins. These proteins are specially developed to help binding assays. They can be used on a variety of assay platforms including ELISA, SPR, Immuno-capture, and Biopanning. Molecule Cat. No. Species Structure Size 2B4 (Biotin-labeled) 2B4-H82F0 2B4 (22-221) Avi 4-1BB (Biotin-labeled) 41B-H82E3 4-1BB (24-186) Avi His 4-1BB (Biotin-labeled) 41B-H82F7 4-1BB (24-186) Avi B7-1 (Biotin-labeled) B71-H82F2 B7-1 (35-242) Avi B7-1 (Biotin-labeled) B71-H82E9 B7-1 (35-242) Avi His B7-2 (Biotin-labeled) CD6-H82E2 B7-2 (26-247) Avi His B7-2 (Biotin-labeled) CD6-H82F5 B7-2 (26-247) Avi B7-H4 (Biotin-labeled) B74-H82E2 B7-H4 (29-258) Avi His B7-H4 (Biotin-labeled) B74-H8222 B7-H4 (29-258) His B7-H5 (Biotin-labeled) B75-H82E1 B7-H5 (33-194) Avi His BTLA (Biotin-labeled) BTA-H82F8 BTLA (31-134) Avi CD155 (Biotin-labeled) CD5-H82F6 CD155 (21-343) Avi

CD27 (Biotin-labeled) TN7-H82F6 CD27 (21-192) Avi CD28 (Biotin-labeled) CD8-H82F2 CD28 (19-152) Avi CD40 (Biotin-labeled) CD0-H82F2 CD40 (21-193) Avi His CD40 (Biotin-labeled) CD0-H82E8 CD40 (21-193) Avi His CD47 (Biotin-labeled) CD7-H82E9 CD47 (19-139) His Avi CD47 (Biotin-labeled) CD7-H82F6 CD47 (19-139) Avi (Biotin-labeled) CT4-H82F3 (37-162) Avi (Biotin-labeled) CT4-C82E5 (37-160) Avi His DNAM-1 (Biotin-labeled) DN1-H82F9 DNAM-1 (19-247) Avi HVEM (Biotin-labeled) HV4-H82F1 HVEM (39-202) Avi OX40 (Biotin-labeled) TN4-H82E4 OX40 (29-216) Avi His OX40 (Biotin-labeled) OX0-H82F7 OX40 (29-216) Avi (Biotin-labeled) PD1-H82E4 (25-167) Avi His (Biotin-labeled) PD1-H82F2 (25-167) Avi His (Biotin-labeled) PD1-M8259 (25-167) (Biotin-labeled) PD1-M82F4 (25-167) Avi (Biotin-labeled) PD1-H82E5 (19-238) Avi His (Biotin-labeled) PD1-H82F3 (19-238) Avi His (Biotin-labeled) PD1-M82F5 (19-238) Avi (Biotin-labeled) PD2-H82E8 (20-219) Avi His SIRP alpha (Biotin-labeled) CDA-H82F2 SIRP alpha (31-370) Avi TIGIT (Biotin-labeled) TIT-H82E5 TIGIT (22-141) Avi His TIGIT (Biotin-labeled) TIT-H82F1 TIGIT (22-141) Avi

Highlight: PD1:PDL1 Inhibitor Screening Assay Kit The interaction of with its ligand will suppress T-cell activation, and allow the tumor to escape from body s immune surveillance. The clinical success of nivolumab has fueled wide spread enthusiasm in studying this pathway. To support rapid and high throughput screening of candidate inhibitory compounds of the PD1 pathway, ACROBiosystems has developed a PD1- inhibitor screening assay kit (Cat. No. EP-101). The assay takes advantage of our in-house developed binding of biotinylated human protein, and employs a simple colorimetric sandwich ELISA platform to assay its binding against immobilized human. Fig. 4 Immobilized human protein can bind biotinylated human -Biotin when detected by Streptavidin-HRP. Fig. 5 Inhibition of - binding by an Anti- neutralizing antibody is measured using the [Biotinylated] : Inhibitor Screening ELISA Assay Pair. Cat. No. Product Name Size EP-101 [Biotin]: Inhibitor Screening Pair 96 tests EP-101 [Biotin]: Inhibitor Screening Pair 480 tests

All PD1 Pathway Proteins Molecule Cat. No. Species Structure Size PD1-H5284 (25-167) Twin-Strep 25ug, 250ug PD1-M5228 (25-167) His PD1-M5259 (25-167) PD1-R5253 (25-167) PD1-R52H2 (25-167) His PD1-RB5251 Rabbit (25-167) PD1-R52H0 Rabbit (25-167) His PD1-C5223 (25-167) His PD1-C5254 (25-167) PD1-M52A4 (21-167) m (Biotin-labeled) PD1-H82E4 (25-167) Avi His (Biotin-labeled) PD1-H82F2 (25-167) Avi His (Biotin-labeled) PD1-M8259 (25-167) (Biotin-labeled) PD1-M82F4 (25-167) Avi (FITC) PD1-HF257 (25-167) (Full length) PD1-HC214 (25-288) 20ug (HPLC-verified) PD1-H5221 (25-167) His (HPLC-verified) PD1-H5257 (25-167) PD1-H5258 (19-238) (HPLC-verified) PD1-H52A3 (19-238) m PD1-H9229 (19-238) His 5ug, 20ug

PD1-H5282 (19-238) Twin-Strep 25ug, 250ug PD1-M5220 (19-238) His PD1-M5251 (19-238) PD1-M52A2 (19-238) m PD1-C5253 (19-238) PD1-C52H4 (19-238) His (Biotin-labeled) PD1-H82E5 (19-238) Avi His (Biotin-labeled) PD1-H82F3 (19-238) Avi His (Biotin-labeled) PD1-M82F5 (19-238) Avi (HPLC-verified) PD1-H5229 (19-238) His PD2-H5220 (20-219) His PD2-H52A5 (20-219) m PD2-M5254 (20-219) PD2-M52A5 (20-219) m PD2-M52E3 (20-219) His (Biotin-labeled) PD2-H82E8 (20-219) Avi His (HPLC-verified) PD2-H5251 (20-219)

Product Highlight: HPLC-Verified Checkpoint Proteins Immune checkpoint proteins are heavily targeted in pharmaceutical research. The quality of these proteins is essential for assay development. In many situations, SDS-PAGE alone is not sufficient for quality control purposes. To address this need, ACROBiosystems has developed a collection of SEC-HPLC verified drug target proteins and biomarkers. The purity of, Tag (HPLC-verified)(Cat. No. PD1-H5257) is greater than 95% as determined by SEC- HPLC. All HPLC-Verified Checkpoint Proteins Molecule Cat. No. Species Structure Size B7-1 B71-H5259 B7-1 (35-242) B7-1 CD0-C52H3 B7-1 (35-242) His B7-2 CD6-C52H5 B7-2 (19-240) His CD40 CD0-H5253 CD40 (21-193) CD47 CD7-H5256 CD47 (19-139) OX40 Ligand OXL-H52Q8 His OX40 Ligand (51-183) PD1-H5221 (25-167) His PD1-H5229 (19-238) His PD1-H5257 (25-167) PD1-H52A3 (19-238) m

PD2-H5251 (20-219) SIRP alpha SIA-H5225 SIRP alpha (31-370) His SIRP alpha SIA-H5251 SIRP alpha (31-370) SIRP alpha SIA-H52A8 SIRP alpha (31-370) m SIRP alpha SIA-H5351 SIRP alpha (31-370)

Product List Molecule Cat. No. Species Structure Size 2B4 2B4-H5224 2B4 (22-221) His 2B4 2B4-H5255 2B4 (22-221) 2B4 (Biotin-labeled) 2B4-H82F0 2B4 (22-221) Avi 4-1BB 41B-H5227 4-1BB (24-186) His 4-1BB 41B-H5258 4-1BB (25-186) 4-1BB 41B-C52H4 4-1BB (24-186) His 4-1BB 41B-M5258 4-1BB (24-211) 4-1BB 41B-M52H7 4-1BB (24-211) His 4-1BB (Biotin-labeled) 41B-H82F7 4-1BB (24-186) Avi 4-1BB (Biotin-labeled) 41B-H82E3 4-1BB (24-186) Avi His 4-1BB Ligand 41L-H5257 4-1BB Ligand (50-254) 4-1BB Ligand 41L-M5257 4-1BB Ligand (104-309) B7-1 (Biotin-labeled) B71-H82E9 B7-1 (35-242) Avi His B7-1 B71-H5228 B7-1 (35-242) His B7-1 CD0-M5259 B7-1 (38-245) B7-1 CD0-C5252 B7-1 (35-242) B7-1 CD0-M5228 B7-1 (38-245) His B7-1 (Biotin-labeled) B71-H82F2 B7-1 (35-242) Avi B7-1 (HPLC-verified) B71-H5259 B7-1 (35-242) B7-1 (HPLC-verified) CD0-C52H3 B7-1 (35-242) His B7-2 CD6-H5223 B7-2 (26-247) His

Product List Molecule Cat. No. Species Structure Size B7-2 CD6-H5257 B7-2 (26-247).B7-2 CD6-M5251 B7-2 (24-245) B7-2 CD6-M52H0 B7-2 (24-245) His B7-2 CD6-C5254 B7-2 (19-240) B7-2 (Biotin-labeled) CD6-H82F5 B7-2 (26-247) Avi B7-2 (Biotin-labeled) CD6-H82E2 B7-2 (26-247) Avi His B7-2 (HPLC-verified) CD6-C52H5 B7-2 (19-240) His B7-H2 B72-H5221 B7-H2 (19-258) His B7-H3 B73-H5253 B7-H3 (29-245) B7-H3 B73-H52E2 B7-H3 (29-245) His B7-H3 B73-M5255 B7-H3 (29-244) B7-H3 B73-M52H4 B7-H3 (29-244) His B7-H4 B74-H5222 B7-H4 (29-258) His B7-H4 (Biotin-labeled) B74-H8222 B7-H4 (29-258) His B7-H4 (Biotin-labeled) B74-H82E2 B7-H4 (29-258) Avi His B7-H5 B75-H5259 B7-H5 (33-194) B7-H5 B75-H52H0 B7-H5 (33-194) His B7-H5 B75-C5220 Rhesus macaque B7-H5 (33-192) His B7-H5 B75-M52H7 B7-H5 (33-191) His B7-H5 (Biotin-labeled) B75-H82E1 B7-H5 (33-194 ) Avi His BTLA BTA-H5255 BTLA (31-134)

BTLA BTA-H5256 BTLA (31-150) BTLA BTA-H52E0 BTLA (31-150) His BTLA BTA-M5253 BTLA (30-176) BTLA BTA-M52E2 BTLA (30-176) His BTLA (Biotin-labeled) BTA-H82F8 BTLA (31-134) Avi CD155 CD5-H5223 CD155 (21-343) His CD155 CD5-H5251 CD155 (21-343) CD155 CD5-H5254 CD155 (21-343) m CD155 (Biotin-labeled) CD5-H82F6 CD155 (21-343) Avi CD160 BY5-H5229 CD160 (27-159) His CD27 CD7-H5254 CD27 (21-192) CD27 (Biotin-labeled) TN7-H82F6 CD27 (21-192) Avi CD27 Ligand TN7-H526x CD27 Ligand (39-193) CD28 CD8-M5257 CD28 (20-149) CD28 CD8-M52H6 CD28 (20-149) His CD28 (Biotin-labeled) CD8-H82F2 CD28 (19-152) Avi CD40 CD0-H5228 CD40 (21-193) His CD40 TN5-M52H8 CD40 (24-193) His CD40 TN5-M5259 CD40 (24-193) CD40 CD0-C52H7 Rhesus macaque CD40 (21-193) His CD40 CD0-C5259 Rhesus macaque CD40 (21-193)

CD40 CD0-C5257 CD40 (21-193) CD40 CD0-C52H6 CD40 (21-193) His CD40 (Biotin-labeled) CD0-H82F2 CD40 (21-193) Avi His CD40 (Biotin-labeled) CD0-H82E8 CD40 (21-193) Avi His CD40 (HPLC-verified) CD0-H5253 CD40 (21-193) CD40 Ligand CDL-M5248 His CD40 Ligand (115-260) CD40 Ligand CDL-M526x CD40 Ligand (115-260) CD40 Ligand CDL-H5248 His CD40 Ligand (108-261) 100ug CD40 Ligand CDL-H5267 CD40 Ligand (113-261) CD47 CD7-H5227 CD47 (19-139) His CD47 CD7-H52A5 CD47 (19-139) m CD47 CD7-M5251 CD47 (19-140) CD47 CD7-R5256 CD47 (19-140) CD47 CD7-R5257 Rabbit CD47 (19-139) CD47 CD7-C5252 CD47 (4-126) CD47 (Biotin-labeled) CD7-H82F6 CD47 (19-139) Avi CD47 (Biotin-labeled) CD7-H82E9 CD47 (19-139) His Avi CD47 (Biotin-labeled) CD7-HA2E9 CD47 (19-139) His Avi CD47 (HPLC-verified) CD7-H5256 CD47 (19-139) CD48 BC1-H5226 CD48 (27-220) His CT4-H5229 (37-162) His 100ug,

CT4-H5255 (37-160) CT4-H5284 (37-162) Twin-Strep 25ug, 250ug CT4-H52A4 (37-162) m CT4-M5256 (36-162) CT4-M52A3 (36-162) m CT4-R5250 Rabbit (36-161) CT4-R5259 (38-161) CT4-C5227 (37-160) His CT4-C5256 (37-160) CT4-M52H5 (36-162) His (Biotin-labeled) CT4-H82F3 (37-162) Avi (Biotin-labeled) CT4-C82E5 (37-160) Avi His 200ug DNAM-1 DN1-H5257 DNAM-1 (19-247) DNAM-1 DN1-H52H6 DNAM-1 (19-247) His DNAM-1 (Biotin-labeled) DN1-H82F9 DNAM-1 (19-247) Avi Galectin-9 LG9-H5244 His Galectin-9 (2-323) GITR GIR-H5228 GITR (26-161) His GITR GIR-M5220 GITR (22-153) His GITR GIR-M5251 GITR (22-153) GITR GIR-R5222 GITR (20-121) His GITR GIR-R5253 GITR (20-121)

GITR GIR-C5255 Rhesus macaque GITR (26-161) GITR Ligand GIL-H526a GITR Ligand (50-177) GITR Ligand GIL-M526x GITR Ligand (47-173) HVEM HVM-H5258 HVEM (39-202) HVEM HVM-H5283 HVEM (39-202) Twin-Strep 25ug, 250ug HVEM HVM-H52E9 HVEM (39-202) His HVEM (Biotin-labeled) HV4-H82F1 HVEM (39-202) Avi ICOS ICS-H5250 ICOS (21-141) LAG-3 LA3-C5252 LAG-3 (18-449) LAG-3 LA3-H5222 LAG-3 (23-450) His LAG-3 LA3-M52H5 LAG-3 (24-442) His LAG-3 LA3-R52H5 LAG-3 (24-442) His LAG-3 LA3-C52A0 LAG-3 (18-449) m 100ug LAG-3 LA3-H52Aa LAG-3 (23-450) m LAG-3 LA3-H5255 LAG-3 (23-450) OX40 OX0-H5224 OX40 (29-216) His OX40 OX0-H5255 OX40 (29-216) OX40 OX0-M5228 OX40 (20-211) His OX40 OX0-M5259 OX40 (20-211) OX40 OX0-R5253 OX40 (20-210) OX40 OX0-R5254 Rabbit OX40 (19-208)

OX40 OX0-C5220 Rhesus macaque OX40 (28-214) His OX40 OX0-C5251 Rhesus macaque OX40 (28-214) OX40 (Biotin-labeled) TN4-H82E4 OX40 (29-216) Avi His OX40 (Biotin-labeled) OX0-H82F7 OX40 (29-216) Avi OX40 Ligand OXL-H526x OX40 Ligand (51-183) OX40 Ligand OXL-M526x OX40 Ligand (49-198) OX40 Ligand (HPLC-verified) OXL-H52Q8 His OX40 Ligand (51-183) PD1-H5284 (25-167) Twin-Strep 25ug, 250ug PD1-M5228 (25-167) His PD1-M5259 (25-167) PD1-M52A4 (21-167) m PD1-R5253 (25-167) PD1-R52H2 (25-167) His PD1-R52H0 Rabbit (25-167) His PD1-RB5251 Rabbit (25-167) PD1-C5223 (25-167) His PD1-C5254 (25-167) (Biotin-labeled) PD1-H82E4 (25-167) Avi His (Biotin-labeled) PD1-H82F2 (25-167) Avi His (Biotin-labeled) PD1-M8259 (25-167) (Biotin-labeled) PD1-M82F4 (25-167) Avi

(FITC) PD1-HF257 (25-167) (Full Length) PD1-HC214 (25-288) 20ug (HPLC-verified) PD1-H5221 (25-167) His (HPLC-verified) PD1-H5257 (25-167) PD1-H9229 (19-238) His 5ug, 20ug PD1-H5258 (19-238) PD1-H5282 (19-238) Twin-Strep 25ug, 250ug PD1-M5220 (19-238) His PD1-M5251 (19-238) PD1-M52A2 (19-238) m PD1-C5253 (19-238) PD1-C52H4 (19-238) His (Biotin-labeled) PD1-H82F3 (19-238) Avi His (Biotin-labeled) PD1-H82E5 (19-238) Avi His (Biotin-labeled) PD1-M82F5 (19-238) Avi (HPLC-verified) PD1-H5229 (19-238) His (HPLC-verified) PD1-H52A3 (19-238) m PD2-H5220 (20-219) His PD2-H52A5 (20-219) m PD2-M5254 (20-219) PD2-M52A5 (20-219) m

PD2-M52E3 (20-219) His (Biotin-labeled) PD2-H82E8 (20-219) Avi His (HPLC-verified) PD2-H5251 (20-219) SIRP alpha (HPLC-verified) SIA-H5225 SIRP alpha (31-370) His SIRP alpha (HPLC-verified) SIA-H5251 SIRP alpha (31-370) SIRP alpha (HPLC-verified) SIA-H52A8 SIRP alpha (31-370) m SIRP alpha (HPLC-verified) SIA-H5351 SIRP alpha (31-370) SIRP alpha (Biotin-labeled) CDA-H82F2 SIRP alpha (31-370) Avi TIGIT TIT-H5254 TIGIT (22-141) TIGIT TIT-H52H3 TIGIT (22-141) His TIGIT TIT-M5257 TIGIT (26-143) TIGIT TIT-M52E6 TIGIT (26-143) His TIGIT TIT-R5258 TIGIT (17-138) TIGIT TIT-R5259 Rabbit TIGIT (16-142) TIGIT TIT-C5223 TIGIT (89-209) His TIGIT TIT-C5254 TIGIT (89-209) TIGIT TIT-H5253 TIGIT (22-141) m TIGIT (Biotin-labeled) TIT-H82E5 TIGIT (22-141) Avi His TIGIT (Biotin-labeled) TIT-H82F1 TIGIT (22-141) Avi TIM-3 TM3-H5229 TIM-3 (22-200) His TIM-3 TM3-H5258 TIM-3 (22-200)

TIM-3 TI3-H5285 TIM-3 (22-200) Twin-Strep 50ug, 250ug TIM-3 TI3-M5252 TIM-3 (20-191 ) TIM-3 TI3-M52H1 TIM-3 (20-191 ) His TIM-3 TI3-C525b TIM-3 (22-201) TIM-3 KI3-H5252 TIM-3 (22-142)

+ 1 800-810-0816 (US/Canada) + 86 400-682-2521 (Asia & Pacific) techsupport@acrobiosystems.com www.acrobiosystems.com 1 Innovation Way, Newark, DE 19711 CKP-EN02E03-OPE-2017-07-20